DELIVER BIOSCIENCES LIMITED

What DELIVER BIOSCIENCES LIMITED does

Deliver Biosciences Limited is a private UK biotechnology company founded in 2019 that is developing a proprietary nanoparticle-based delivery platform for in vivo genetic engineering of cells. The platform, branded ImmTune, consists of customizable nanoparticle vectors that carry DNA and mRNA payloads directly to specific cell types in vivo while avoiding accumulation in off-target organs such as the liver. Its lead product candidate is an in vivo CAR-T cell therapy that delivers a chimeric antigen receptor gene to T-cells inside the patient, eliminating the need for the complex ex vivo manufacturing and supply chain associated with conventional CAR-T therapies. The platform's programmable targeting domains are designed to address stem cells, neurons, and heart cells in addition to T-cells, opening potential applications across autoimmune, neurodegenerative, cardiovascular, and infectious disease indications.

The company is co-founded by CEO Dr. Bakul Gupta (PhD UNSW Australia; postdoctoral fellow at Imperial College London) and CSO Dr. George Tetley (PhD and postdoc at Cambridge; previously collaborated with MedImmune/AstraZeneca). Deliver Biosciences generates revenue, in principle, through technology licensing, co-development agreements, and research collaborations with pharmaceutical and biotech partners, but the company is pre-commercial and the source data explicitly notes no revenue is disclosed and no publicly disclosed pricing exists for the platform. GTM runs through enterprise licensing and strategic partnerships, with named collaborators including King's College London, the Cell and Gene Therapy Catapult, Imperial College London, and Fortis Life Sciences, supported by non-dilutive grant funding from Innovate UK, Merck's emerging biotechs grant programme, and Fortis' AbNano VHH Discovery Grant. Advisors include Dr. Lucas Harrington (Mammoth Biosciences co-founder, SciFounders partner), Dr. Scott Dylla (Stemcentrx co-founder, sold to AbbVie), and Dr. Martin Pule (Autolus founder, UCL CAR-T specialist).

The company is headquartered in London's King's Cross, operates primarily in Europe, and competes in the non-viral vector and in vivo cell engineering space alongside both viral vector incumbents and emerging lipid nanoparticle approaches. Ownership is founder-led with grant and advisor-driven funding rather than disclosed venture equity, and the firm targets a horizontal platform opportunity spanning multiple therapeutic areas rather than a single-asset commercialization path.

Name

DELIVER BIOSCIENCES LIMITED

Legal name

Deliver Biosciences Limited

Website

https://deliverbio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Deliver Biosciences Limited is a UK-based, pre-commercial biotech developing the ImmTune nanoparticle delivery platform for in vivo genetic engineering of cells, with a lead in vivo CAR-T therapy for cancer and pipeline potential across autoimmune, neurodegenerative, and cardiovascular indications.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy Delivery Platforms

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

Keywords

• Nanoparticle drug delivery
• In vivo gene therapy
• Cell therapy platforms
• Non-viral delivery vectors
• CAR-T immunotherapy

Headquarters

HQ city

Truro

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Platform Licensing and Co-development: The company generates revenue through licensing its nanoparticle delivery platform technology to pharmaceutical and biotech partners, co-development agreements for specific therapeutic programs, and potential milestone payments from partners advancing therapies through clinical development.
2. Strategic Partnerships and Collaborations: Revenue derived from research collaborations with pharmaceutical companies, academic institutions, and biotech partners who require targeted drug delivery capabilities. Partnerships may include upfront payments, research funding, and downstream milestone or royalty arrangements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Deliver Biosciences develops a proprietary nanoparticle-based delivery platform (ImmTune) that genetically engineers specific cells inside patients for cell and gene therapies. The lead product candidate is an in vivo CAR-T cell therapy that delivers a chimeric antigen receptor gene directly to T-cells, eliminating the need for ex vivo manufacturing. The platform is designed to transport diverse payloads (DNA, mRNA) to multiple cell types including T-cells, stem cells, neurons, and heart cells.

Product overview

Deliver Biosciences is developing a nanoparticle-based delivery platform with its ImmTune delivery vector technology at the core. The company is building multiple therapeutic programs on this platform, with its lead product being an in vivo CAR-T cell therapy for cancer immunotherapies. The platform technology is designed to be versatile, allowing modification of different cell types including stem cells, neurons, and heart cells for addressing various indications.

Differentiator

Problem solved

Functional benefit

Brands

• ImmTune: nanoparticle-based delivery vector technology for in vivo CAR-T therapies

Products and services

• Nanoparticle Delivery Platform

Quantifiable outcome

• Eliminates need for specialised manufacturing centres and long, expensive supply chains

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Fortis Life SciencescoreStrategic or Co-development Partner · 12 May 2026Fortis Life Sciences awarded Deliver Biosciences the inaugural 2026 AbNano VHH Discovery Grant, providing access to AbNano's single-domain antibody discovery services for targeted drug delivery research. The grant supports Deliver Biosciences' work on in vivo CAR-T therapies and gene therapy platforms targeting HIV, sickle cell disease, and neurodegenerative disorders.
• King's College LondoncoreStrategic or Co-development Partner · 1 March 2022Collaboration partner for the Biomedical Catalyst Grant awarded by Innovate UK. The partnership focuses on developing ImmTune's delivery vector technology and preparing it for clinical trials over a 3-year period.
• Cell and Gene Therapy CatapultcoreStrategic or Co-development Partner · 1 March 2022Collaborative partner alongside King's College London for the Biomedical Catalyst Grant to develop ImmTune delivery vector technology and advance it toward clinical trials.
• Imperial College LondoncoreStrategic or Co-development PartnerFounding institution and research partner. Co-founder Dr Bakul Gupta completed postdoctoral training at Imperial College London under Prof. Dame Molly Stevens. The institution hosts the Purple Plaque ceremony recognising Deliver Biosciences' achievements and maintains ongoing collaborative research relationships.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Beam Therapeutics: Beam is a clinical-stage base editing company with both ex vivo and in vivo programs. Comparable as a precision genetic medicines developer that depends on innovative delivery (including LNPs) to reach target cells.
• Intellia Therapeutics: Intellia is a clinical-stage CRISPR/Cas9 leader with significant in vivo gene-editing capabilities using LNP delivery. Comparable as a leading player developing non-viral in vivo delivery for gene and cell therapies, with substantially greater capital and clinical progress.
• Verve Therapeutics: Verve is a clinical-stage in vivo base editing company using LNPs to deliver gene-editing cargo to the liver and other tissues. Comparable as a developer of in vivo non-viral delivery platforms for therapeutic gene editing, with overlap on the cardiovascular indication pathway.

Others

• Mammoth Biosciences: Mammoth is a CRISPR diagnostics and gene-editing therapeutics company co-founded by Deliver Bio advisor Dr. Lucas Harrington. Included as a strategic ecosystem partner given the direct advisory relationship and overlapping interest in CRISPR/gene-editing delivery.

Direct peers

• Umoja Biopharma: Umoja is developing in vivo CAR-T and iPSC-derived immune cell therapies using targeted delivery approaches. Direct competition in the in vivo cell engineering category, with overlapping indications in haematologic cancers.
• Capstan Therapeutics: Capstan is a direct in vivo CAR-T competitor using LNP-delivered mRNA to reprogram T-cells inside the body. Both companies target the same problem (eliminating ex vivo CAR-T manufacturing) with a non-viral delivery approach, making them the closest comparable in the in vivo cell therapy space.
• Autolus Therapeutics: Autolus is a UK-based clinical-stage CAR-T company founded by Deliver Bio advisor Dr. Martin Pule. It is the closest UK-headquartered CAR-T peer and the most direct incumbent in the lead product category, even though it uses ex vivo manufacturing.

Emerging players

• Generation Bio: Generation Bio is developing non-viral lipid nanoparticle-based gene delivery for both rare and prevalent diseases. Comparable as a non-viral delivery platform company targeting multiple cell types, though with broader scope and different cargo focus.
• Lexeo Therapeutics: Lexeo is developing AAV-based and non-viral gene therapies for cardiovascular and CNS indications. Partial overlap in target tissues and indications (cardiovascular, neurodegenerative diseases), though Lexeo's lead programs are still primarily viral-vector based.
• Orna Therapeutics: Orna is developing circular RNA therapeutics delivered via LNP, with a focus on in vivo CAR-T and oncology applications. Direct partial overlap as an in vivo CAR-T developer using non-viral nanoparticle delivery.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/DeliverBio
• LinkedInlinkedin.com/company/deliverbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DELIVER BIOSCIENCES LIMITED